$EPIX
ESSA Pharma Inc

2020 Q4 Form 10-Q Financial Statement

#000155837021000895 Filed on February 11, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.210M $2.140M
YoY Change 3.27% 71.2%
% of Gross Profit
Research & Development $4.486M $2.587M
YoY Change 73.39% 102.12%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.696M $4.942M
YoY Change 35.49% 95.33%
Operating Profit
YoY Change
Interest Expense $130.0K $50.00K
YoY Change 160.0% -129.41%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.564M -$4.891M
YoY Change 34.2% 81.16%
Income Tax -$35.15K -$278.0K
% Of Pretax Income
Net Earnings -$6.529M -$4.613M
YoY Change 41.52% 70.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$195.9K -$222.1K
COMMON SHARES
Basic Shares Outstanding 33.60M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.50M $45.90M
YoY Change 62.31% 276.23%
Cash & Equivalents $52.48M $45.93M
Short-Term Investments $22.00M
Other Short-Term Assets $1.100M $500.0K
YoY Change 120.0% 25.0%
Inventory
Prepaid Expenses $1.138M
Receivables $200.0K $400.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $75.90M $46.80M
YoY Change 62.17% 265.63%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K
YoY Change 0.0% 50.0%
Total Long-Term Assets $277.6K $600.0K
YoY Change -53.73% 50.0%
TOTAL ASSETS
Total Short-Term Assets $75.90M $46.80M
Total Long-Term Assets $277.6K $600.0K
Total Assets $76.17M $47.40M
YoY Change 60.71% 259.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.376M $1.100M
YoY Change 25.07% 57.14%
Accrued Expenses $609.7K $100.0K
YoY Change 509.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $2.035M $1.200M
YoY Change 69.61% -66.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0% -96.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.035M $1.200M
Total Long-Term Liabilities $0.00 $100.0K
Total Liabilities $2.074M $1.300M
YoY Change 59.51% -79.69%
SHAREHOLDERS EQUITY
Retained Earnings -$87.50M
YoY Change
Common Stock $134.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.10M $45.84M
YoY Change
Total Liabilities & Shareholders Equity $76.17M $47.40M
YoY Change 60.71% 259.09%

Cashflow Statement

Concept 2020 Q4 2019 Q4
OPERATING ACTIVITIES
Net Income -$6.529M -$4.613M
YoY Change 41.52% 70.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.943M -$3.361M
YoY Change 17.32% 81.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.9K -4.036M
YoY Change -103.74% 404.52%
NET CHANGE
Cash From Operating Activities -3.943M -3.361M
Cash From Investing Activities 0.000
Cash From Financing Activities 150.9K -4.036M
Net Change In Cash -3.836M -7.388M
YoY Change -48.08% 178.8%
FREE CASH FLOW
Cash From Operating Activities -$3.943M -$3.361M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001633932
CY2020Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2020Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q4 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33605383
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32064411
CY2020Q4 dei Document Type
DocumentType
10-Q
CY2020Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q4 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 dei Entity File Number
EntityFileNumber
001-37410
CY2020Q4 dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
CY2020Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2020Q4 dei Entity Address Country
EntityAddressCountry
CA
CY2020Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2569713
CY2020Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
CY2020Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
CY2020Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2020Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2020Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
CY2020Q4 dei City Area Code
CityAreaCode
778
CY2020Q4 dei Local Phone Number
LocalPhoneNumber
331-0962
CY2020Q4 dei Security12b Title
Security12bTitle
Common Shares
CY2020Q4 dei Trading Symbol
TradingSymbol
EPIX
CY2020Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.64
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
22011337
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
231191
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
309538
CY2020Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q4 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33780064
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52484512
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56320763
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
22016344
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1137723
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600128
CY2020Q4 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
27581
CY2020Q3 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
55162
CY2020Q4 us-gaap Assets Current
AssetsCurrent
75897351
CY2020Q3 us-gaap Assets Current
AssetsCurrent
80296928
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
277637
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
277637
CY2020Q4 us-gaap Assets
Assets
76174988
CY2020Q3 us-gaap Assets
Assets
80574565
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2005389
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1144230
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29988
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59094
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2035377
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1203324
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
38246
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
CY2020Q4 us-gaap Liabilities
Liabilities
2073623
CY2020Q3 us-gaap Liabilities
Liabilities
1330700
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33605383
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32064411
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
134387525
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
131086364
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29289327
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31204284
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87499008
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80970304
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74101365
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76174988
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80574565
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2139165
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
6695870
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
4941814
CY2020Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7196
CY2019Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6209
CY2020Q4 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
35691
CY2019Q4 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
100965
CY2020Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
89130
CY2019Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-56633
CY2020Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6563853
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4485772
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2587148
CY2020Q4 epix Financing Costs
FinancingCosts
1181
CY2019Q4 epix Financing Costs
FinancingCosts
215501
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2208917
CY2019Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4891273
CY2020Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-35149
CY2019Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-278000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-6528704
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-4613273
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33343488
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20762374
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-6528704
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-4613273
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27581
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27581
CY2020Q4 us-gaap Accretion Expense
AccretionExpense
1181
CY2019Q4 us-gaap Accretion Expense
AccretionExpense
4422
CY2020Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
89130
CY2019Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-56633
CY2020Q4 epix Interest Income Operating Activities
InterestIncomeOperatingActivities
5007
CY2019Q4 epix Interest Income Operating Activities
InterestIncomeOperatingActivities
0
CY2020Q4 epix Finance Expense Operating Activities
FinanceExpenseOperatingActivities
0
CY2019Q4 epix Finance Expense Operating Activities
FinanceExpenseOperatingActivities
211079
CY2020Q4 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-13952
CY2019Q4 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
11510
CY2020Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1204985
CY2019Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1253621
CY2020Q4 epix Income Tax Expense Recovery Operating Activities
IncomeTaxExpenseRecoveryOperatingActivities
0
CY2019Q4 epix Income Tax Expense Recovery Operating Activities
IncomeTaxExpenseRecoveryOperatingActivities
278000
CY2020Q4 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-102308
CY2019Q4 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-10136
CY2020Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-462405
CY2019Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-143675
CY2020Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
867841
CY2019Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-162976
CY2020Q4 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
CY2019Q4 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2000
CY2020Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3942588
CY2019Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3360612
CY2020Q4 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
30287
CY2019Q4 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
29405
CY2020Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2019Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
314603
CY2020Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
153701
CY2019Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
149
CY2019Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
227864
CY2020Q4 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
27369
CY2019Q4 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2020Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2019Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
3199799
CY2020Q4 epix Repayments Of Final Payment Of Debt
RepaymentsOfFinalPaymentOfDebt
0
CY2019Q4 epix Repayments Of Final Payment Of Debt
RepaymentsOfFinalPaymentOfDebt
688000
CY2020Q4 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2019Q4 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
32235
CY2020Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150932
CY2019Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4036178
CY2020Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-44595
CY2019Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8487
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3836251
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7388303
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56320763
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53322723
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52484512
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45934420
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
48981829
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
10652
CY2019Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
227864
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1253621
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-4613273
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
45839389
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2020Q4 epix Prefunded Warrant Exercised Value
PrefundedWarrantExercisedValue
149
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153701
CY2020Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27369
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204985
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-6528704
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74101365
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
95150
CY2020Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
124528
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1137723
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600128
CY2020Q4 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. On October 30, 2020 the Company’s Common Shares delisted in Canada from the TSX Venture Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of December 31, 2020, no products are in commercial production or use.</p>
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
604011
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
825014
CY2020Q4 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
438562
CY2020Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
650586
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375781
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
678643
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
609711
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
310604
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
19897
CY2020Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
154983
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2005389
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1144230
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27581
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
137905
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55162
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27581
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27581
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2019Q4 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
4422
CY2019Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
29405
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
140503
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
59094
CY2020Q4 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
1181
CY2020Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
30287
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
29988
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.120
CY2020Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3M
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
CY2020Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
89130
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
38246
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
38246
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1122461
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4218000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
416
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.20
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
30461
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.46
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1524646
CY2020Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.00
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
42207
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
42000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.40
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6750023
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.24
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2071960
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.52
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6750023
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M14D
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
171716
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1524646
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4218000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.52
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.63
CY2019Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12393092
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.31
CY2020 epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3120115
CY2020 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.08
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.73
CY2020Q4 epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
1493504
CY2020Q4 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
0.00
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7779473
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.06
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7779473
CY2020Q4 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 epix Working Capital
WorkingCapital
73861974

Files In Submission

Name View Source Status
0001558370-21-000895-index-headers.html Edgar Link pending
0001558370-21-000895-index.html Edgar Link pending
0001558370-21-000895.txt Edgar Link pending
0001558370-21-000895-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20201231.xsd Edgar Link pending
tmb-20201231x10q.htm Edgar Link pending
tmb-20201231x10q001.jpg Edgar Link pending
tmb-20201231x10q_htm.xml Edgar Link completed
tmb-20201231xex31d1.htm Edgar Link pending
tmb-20201231xex31d2.htm Edgar Link pending
tmb-20201231xex32d1.htm Edgar Link pending
tmb-20201231_cal.xml Edgar Link unprocessable
tmb-20201231_def.xml Edgar Link unprocessable
tmb-20201231_lab.xml Edgar Link unprocessable
tmb-20201231_pre.xml Edgar Link unprocessable